button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus placebo plus SoC
sintillimab plus SoC vs. placebo plus SoC 1 -1060 [-1975; -145] /10000
51/266 vs. 39/131		-2354 [-3361; -1348] /10000
112/266 vs. 86/131		-
versus Standard of Care (SoC)
cemiplimab vs. Standard of Care (SoC) 1 -949 [-1648; -251] /10000
108/356 vs. 141/354		-1755 [-2444; -1067] /10000
201/356 vs. 262/354		-
durvalumab alone vs. Standard of Care (SoC) 1 -551 [-1153; 51] /10000
278/374 vs. 297/372		--

mNSCLC - L1 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 negative

versus pemetrexed plus platin
nivolumab plus SoC vs. pemetrexed plus platin 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 3 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
cemiplimab vs. Standard of Care (SoC) 1 -1277 [-2034; -519] /10000
70/283 vs. 105/280		-1841 [-2632; -1051] /10000
147/283 vs. 197/280		-
durvalumab alone vs. Standard of Care (SoC) 1 -1275 [-2235; -316] /10000
108/163 vs. 128/162		-411 [-1431; 610] /10000
106/163 vs. 112/162		-
nivolumab alone vs. Standard of Care (SoC) 2 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
pembrolizumab alone vs. Standard of Care (SoC) 4 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-

mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 2 -860 [-1597; -122] /10000
179/359 vs. 197/337		-1536 [-2077; -995] /10000
338/511 vs. 379/465		-
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 -735 [-1525; 56] /10000
226/451 vs. 131/228		-990 [-1576; -404] /10000
347/451 vs. 198/228		-
versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin 1 -56 [-1519; 1408] /10000
13/60 vs. 14/63		-1405 [-3147; 337] /10000
23/60 vs. 33/63		-
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 -559 [-1249; 132] /10000
228/343 vs. 245/340		-628 [-1204; -52] /10000
270/343 vs. 289/340		-
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 -1213 [-2005; -421] /10000
85/278 vs. 120/281		-1543 [-2336; -750] /10000
152/278 vs. 197/281		-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons